Home › Atopic Dermatitis (Eczema) › Michigan
Atopic Dermatitis (Eczema) clinical trials in Michigan
14 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Michigan.
Cities in Michigan
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- and 3 more
RecruitingObservational study
Ages 12 and older · All sexes · Updated Sep 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
RecruitingObservational study
Ages 12 to 89 · All sexes · Updated Sep 15, 2026 · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
RecruitingPhase 3
6 Months – 11 Years · All sexes · Updated Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
RecruitingPhase 3
Ages 18 to 63 · All sexes · Updated Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- and 1 more
RecruitingObservational study
Ages 12 and older · All sexes · Updated Mar 13, 2026 · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
RecruitingHealthy volunteers welcome
Ages 10 to 55 · All sexes · Updated Nov 25, 2025 · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 6, 2025 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jan 24, 2025 · NCT06524635From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.